SHH and medulloblastoma: At least one driver mutation was assigned to >95% of medulloblastomas pertaining to the SHH group, characterized by genetic events targeting the canonical SHH signaling pathway (PTCH1 mutations in 43% of cases) and by frequent somatic alterations involving acetyltransferase complexes (BREBBP, KAT6B, EP300, BRAF1, and KANSL1) [170] (Figure 7 and Figure 8).